Hernandez, D., & Reilly, M
Since then, a number of triple agonists have entered clinical development, with one in phase three clinical studies but have yet to reach the market (Capozzi, DiMarchi, Tschp)
Elle est utilise pour traiter la carence en carnitine et les affections associes
DPP4i, dipeptidyl peptidase-4 inhibitor
L-carnitine exerts a buffer effect that helps attenuate this accumulation
In the ESPRIT trial [27], 11,255 patients with hypertension aged 50 years or older with a high cardiovascular risk were randomized to the intensive treatment group targeting a systolic blood pressure less than 120 mmHg or the standard treatment group targeting less than 140 mmHg